Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Corporate Presentations
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Apr 19, 2018

Biocentury – Promis Identifies New Beta Amyloid Epitope To Treat AD

Mar 7, 2018

As Vtv data nearing in April, Promis AD bid a contender

Jan 13, 2018

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds

Nov 29, 2017

Routes are opening up potentially to prevent or reverse damage that leads to the disease

Nov 28, 2017

New Alzheimer’s disease candidate selectively targets toxic AβO

Nov 7, 2017

Dementia now Britain's biggest killer, overtaking heart disease for first time

Nov 6, 2017

Westwood One Radio: Alzheimer’s Disease

Oct 17, 2017

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease

Sep 26, 2017

Axovant to pull plug on Alzheimer's drug after key study fails

Sep 20, 2017

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy